Peptide brands, and the question that comes before the marketing

Most categories in this industry are decided on the website. Peptides are the category where the file can stop earlier than that, because the first question is not how the product is described but whether it is something a compounder may lawfully prepare for a patient at all.

Brands in this space are frequently unprepared for that question, having built a catalogue from what a supplier offered rather than from what a pharmacy may compound.

The structural question

For each substance in your catalogue, a reviewer wants to establish what it is and on what basis your compounder prepares it. Not what it does. What it is, under what authority, for a patient with a prescription.

The uncomfortable answer for some catalogues is that nobody in the business knows. The substance arrived through a supplier relationship, the pharmacy prepares it, and the regulatory basis was never established by anyone. That is not a marketing problem and no rewrite reaches it.

Establish it before you file, in writing, per substance:

• The substance, named precisely rather than by a marketing name.
• The compounder, its registration type and its permitted scope.
• The basis on which the compounder considers the preparation within that scope.
• Whether the preparation is the same one your website describes.

If your compounder cannot answer the third question in writing, you have a finding, and it is one you cannot close from your side, which is the same problem your pharmacy partner is part of your application describes in a different setting.

Research-use framing does not travel

A substantial part of this market grew from a grey channel where products were sold with research-use labelling and disclaimers stating they were not for human consumption, while the surrounding marketing described dosing for humans.

On a consumer telehealth site that framing is worse than useless. A disclaimer contradicted by the page it sits on is not a protection, it is evidence that the business knew. A reviewer reads the whole page, and so does everybody else.

If a product is prescribed and dispensed to a patient, describe it as what it is. If it cannot be described that way, it does not belong in a telehealth catalogue.

The claims problem, which is the same one

Nothing about this category changes the marketing rules. A compounded preparation has not been reviewed for safety, effectiveness or quality, and the sentences that draw enforcement elsewhere draw it here.

The pattern to watch for specifically is borrowed science. Peptide marketing leans heavily on mechanism: a study in a journal, an animal model, a pathway diagram. Presenting mechanism as outcome is an effectiveness claim wearing a lab coat, and it is the version of the claim that copywriters in this category believe is safe.

Our index of FDA warning letters covering compounded GLP-1 marketing is a useful calibration even for brands outside that specific category: it counts the letters and codes each by what it cites, and those citations are the three things this category writes without thinking, which are approval, equivalence and outcome. The enforcement vocabulary is the same.

Stacking, protocols and dosing content

Brands in this category publish protocols: combinations, cycles, dosing schedules, and content explaining how to run them. That content is marketing regardless of where it sits, and it makes claims about products the patient has not yet been assessed for.

Two consequences. It describes outcomes, which is an effectiveness claim. And it describes a model where the patient chooses the protocol and the clinician confirms it, which inverts the prescribing decision.

Where the clinical model genuinely involves combination therapy, describe it as a clinician's decision made for an individual after assessment, which is both more accurate and less exposed.

The supply chain question behind the eligibility question

Where the active ingredient comes from is part of what makes a preparation lawful for a compounder to make, and it is the part of the file a telehealth brand almost never holds.

You do not need to become an expert in it. You do need to be able to say, per substance, that your compounder has established its source and considers it appropriate, and to have that in writing rather than as an assurance given on a call. A brand that cannot produce it is relying on a partner's compliance function that it has never examined.

Ask three questions and keep the answers. Where does the ingredient come from, what evidence of identity and quality accompanies it, and what would change if that supplier stopped. The third question is a business continuity question until the day it becomes the reason a product line disappears mid-review.

The catalogue changes under you

This category moves faster than the paperwork. Suppliers add substances, pharmacies stop preparing others, and a marketing team lists whatever is available.

That is why the eligibility work here is a recurring job rather than a pre-submission one. A quarterly reconciliation between what the site sells, what the pharmacy prepares and what the file says is the whole of the maintenance, and it is the thing that stops a certified brand quietly acquiring a product nobody assessed.

What to expect from the review

Expect the structural questions first and expect them to be specific per substance. Expect the pharmacy documentation to be requested if it was not supplied. Expect the intake to be examined for whether it screens or sells.

And expect a longer review than a single-product brand receives, because a catalogue of a dozen substances is a dozen separate eligibility questions, which is what compounded products and certification eligibility means when it says the category brings a closer read.

The decision worth making before you file

Trim the catalogue. Most brands in this space carry a long tail of substances that contribute little revenue and most of the regulatory exposure, kept because a supplier offered them and removing them felt like losing ground.

A shorter catalogue that you can fully evidence is a materially better application than a long one with three substances nobody can account for, and it is a better business, because the tail is also where the supply chain is thinnest.

Decide that before submission. Changing the shape of the catalogue during a review is exactly the kind of mid-flight change that generates questions rather than answering them.